Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

American Journal of Hematology

Volumn 88, Issue 4, 2013, Pages 312-316

  Pardanani, Animesh ^a   Finke, Christy ^a   Abdelrahman, Ramy A ^a   Lasho, Terra L ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FERRITIN; HEMOGLOBIN; HEPCIDIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INFLAMMATION; IRON; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84875578130     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23406     Document Type: Article

References (21)

1. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: The mayo clinic experience. Mayo Clin Proc 2012;87:25-33.
2. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-1363.
3. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-1127.
4. Leitch HA, Chase JM, Goodman TA, et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol 2010;28:40-48.
5. Winder A, Lefkowitz R, Ghoti H, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 2008;142:669-671.
6. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
7. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.
8. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
9. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: Regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
10. Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012;87:392-400.
11. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
12. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia 2011;25:82-88.
13. Cheng PP, Jiao XY, Wang XH, et al. Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia. Clin Exp Med 2011;11:33-42.
14. Cheng PP, Sun ZZ, Jiang F, et al. Hepcidin expression in patients with acute leukaemia. Eur J Clin Invest 2012;42:517-525.
15. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-2284.
16. Santini V, Girelli D, Sanna A, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One 2011;6:e23109.
17. Alessandrino EP, Angelucci E, Cazzola M, et al. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo. Am J Hematol 2011;86:897-902.
18. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
19. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92:583-588.
20. Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol 2012;87:977-983.
21. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: More than meets the eye? Blood 2009;114:5251-5255.